Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Lateral Femoral Cutaneous Nerve Block (LFCN) in ACL Reconstruction With MacFL-type Lateral Tenodesis (RECUP- NCLC)

The goal of this randomized clinical trial is to evaluate whether adding an ultrasound-guided lateral femoral cutaneous nerve (LFCN) block to a standard regional analgesia protocol improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction combined with MacIntosh-type lateral extra-articular tenodesis.

The main question the study aims to answer is whether adding an LFCN block to an adductor canal block (ACB) and an iPACK block improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.

The study will also assess:

  • Preservation of quadriceps function, assessed by the ability to perform a straight leg raise (SLR).
  • Postoperative pain at the lateral thigh graft harvest site and knee, at rest and during mobilization.
  • Cumulative oral opioid consumption during the first 48 hours after surgery.
  • Incidence of postoperative nausea and vomiting (PONV).
  • Time to first postoperative ambulation.
  • Patient satisfaction with analgesic management.

Adverse events and complications related to regional anesthesia, including sensory disturbances, hematoma, infection, and signs of local anesthetic systemic toxicity.

Participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. All participants will undergo ACL reconstruction combined with MacIntosh-type lateral extra-articular tenodesis and will receive an ACB and an iPACK block. Participants in the experimental group will additionally receive an ultrasound-guided LFCN block.

Postoperative assessments will include QoR-15, pain scores, opioid consumption, PONV, quadriceps function, ambulation, patient satisfaction, and safety assessments during the first 48 hours after surgery and at 1 month. The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

108

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 60 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult patients aged 18 to 60 years;
  • Presenting a primary anterior cruciate ligament (ACL) tear;
  • Scheduled for ACL reconstruction associated with MacIntosh-type lateral extra-articular tenodesis (or equivalent technical variant using an iliotibial band 'ITB' graft);
  • Surgery to be performed under general anesthesia;
  • Planned management in outpatient surgery or short-stay hospitalization after the operation;
  • Understanding the validated French version of the QoR-15 questionnaire;
  • Having given their informed consent to participate in the study;
  • Patients affiliated with or benefiting from a social security scheme.

Exclusion Criteria:

  • Patients having allergy to local anesthetics or a contraindication to peripheral nerve blocks;
  • Patients having neuropathy of the lower limbs;
  • Patients having coagulation disorders or on major anticoagulation;
  • Patients suffering from chronic pain that requires more than 30 mg morphine-equivalents per day;
  • Patients undergoing revision ACL reconstruction;
  • Patients with pre-existing hypoesthesia of the lateral thigh (e.g. known meralgia paresthetica);
  • Patients unable to complete the questionnaires or expressing refusal to participate;
  • Pregnant women, women of childbearing age without effective contraception), or women breastfeeding;
  • Protected adults under guardianship, curatorship or other legal protection, deprived of liberty or under guardianship or curatorship, or unable to give consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: ACB + iPACK + LFCN Block

Participants will undergo anterior cruciate ligament reconstruction combined with MacIntosh-type lateral extra-articular tenodesis. They will receive an adductor canal block (ACB) and an iPACK block as the standard regional analgesia protocol, with the addition of an ultrasound-guided lateral femoral cutaneous nerve (LFCN) block.

Ultrasound-guided adductor canal block administered as part of the standard regional analgesia protocol for ACL reconstruction with MacIntosh-type lateral extra-articular tenodesis.

Ultrasound-guided iPACK block (infiltration between the popliteal artery and the posterior capsule of the knee) administered as part of the standard regional analgesia protocol.

Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block administered in addition to the adductor canal block and iPACK block in the experimental arm.

Comparateur actif: ACB + iPACK

Participants will undergo anterior cruciate ligament reconstruction combined with MacIntosh-type lateral extra-articular tenodesis. They will receive an adductor canal block (ACB) and an iPACK block without an additional lateral femoral cutaneous nerve (LFCN) block.

Ultrasound-guided adductor canal block administered as part of the standard regional analgesia protocol for ACL reconstruction with MacIntosh-type lateral extra-articular tenodesis.

Ultrasound-guided iPACK block (infiltration between the popliteal artery and the posterior capsule of the knee) administered as part of the standard regional analgesia protocol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Quality of Recovery (QoR-15) Score
Délai: 24 hours after surgery

The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The score will be assessed preoperatively before administration of regional anesthesia and again 24 hours after surgery. The primary analysis will compare the QoR-15 score at 24 hours between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference.

24 hours after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Preservation of Quadriceps Function
Délai: 24 hours after surgery

Quadriceps function will be assessed by the ability to perform a straight leg raise (SLR) at 24 hours postoperatively.

24 hours after surgery
Postoperative Lateral Thigh and Knee Pain
Délai: 6, 24, and 48 hours after surgery

Pain intensity at the lateral thigh graft harvest site and knee will be assessed at rest and during mobilization using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst pain imaginable).

6, 24, and 48 hours after surgery
Cumulative Postoperative Opioid Consumption
Délai: Day 0, Day 1, and Day 2 after surgery

Total oral opioid consumption will be recorded and converted to morphine milligram equivalents (MME).

Day 0, Day 1, and Day 2 after surgery
Postoperative Nausea and Vomiting
Délai: Day 0, Day 1, and Day 2 after surgery

The incidence of postoperative nausea and vomiting (PONV) will be recorded during the postoperative period.

Day 0, Day 1, and Day 2 after surgery
Time to First Postoperative Ambulation
Délai: Day 1 after surgery

Time from surgery to first postoperative ambulation will be recorded in hours.

Day 1 after surgery
Patient Satisfaction With Analgesic Management
Délai: Day 1 and Day 2 after surgery

Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale.

Day 1 and Day 2 after surgery
Safety and Adverse Events Related to Regional Anesthesia
Délai: Day 1 and 1 month after surgery

Adverse events and complications potentially related to regional anesthesia will be recorded, including hypoesthesia or paresthesia of the lateral thigh, abnormal sensory disturbances, hematoma at the LFCN block site, infection, and signs of local anesthetic systemic toxicity.

Day 1 and 1 month after surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Yoann ELMALEH, Hôpital Privé Claude Galien

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 novembre 2027

Achèvement de l'étude (Estimé)

1 novembre 2027

Dates d'inscription aux études

Première soumission

3 novembre 2026

Première soumission répondant aux critères de contrôle qualité

3 novembre 2026

Première publication (Réel)

9 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner